CDC Panel Recommends RSV Vaccines for Adults 65 Years and Older

CDC Panel Recommends RSV Vaccines for Adults 65 Years and Older

Adults 65 and older should receive one of the newly approved RSV vaccines, an advisory committee for the Centers for Disease Control and Prevention decided Wednesday.

The committee voted 9-5 to recommend two different RSV vaccines for adults 65 and older, from pharmaceutical giants Pfizer and GSK. Thirteen members also voted to recommend vaccinations for adults 60 to 64 years of age based on individual risk levels and in consultation with physicians, with one committee member abstaining.

Respiratory syncytial virus causes a lower respiratory tract illness that is generally mild to most healthy adults. But in severe cases, RSV can lead to pneumonia or bronchiolitis, which inflames the airways and clogs them with mucus.

Older people are particularly vulnerable to serious outcomes: RSV Bush up to 10,000 people age 65 and older each year in the US

The Pfizer and GSK shots are the only RSV vaccines approved by the Food and Drug Administration, but none are publicly available yet. The FDA approved each shot for adults 60 and older last month, but as with any new vaccine, the CDC must recommend the shots before they can be distributed or administered.

After Wednesday’s vote, the final step is for CDC Director Dr. Rochelle Walensky to formally endorse the vaccines, which she is expected to do soon.

Even after that, the shots can be hard to find right away. Dr. Phil Dormitzer, GSK’s senior vice president and global head of vaccine research and development, said last month that the company aims to make its RSV vaccine available in the fall so older adults have face protection. to the next season of the RSV, which usually peaks in the winter.

Walgreens said it hopes to offer the new vaccines in pharmacies across the country in time for the upcoming respiratory disease season. Appointments can be made online, by phone or through the Walgreens app once the shots are available, the company said. CVS Pharmacy said it will also work with vaccine manufacturers to ensure access to RSV vaccines at more than 9,000 locations.

The FDA approved GSK’s RSV vaccine, called Arexvy, based on the results of a late stage clinical trial which showed that a single dose reduced the risk of symptomatic disease by 83% and severe disease by 94%.

Pfizer’s single-dose vaccine, Abrysvo, was approved based on a similar trial in which it reduced the risk of symptomatic disease by up to 86%. The most recent data presented to the CDC on Wednesday showed that protection dropped slightly around 18 months after vaccination, although it was still 79%.

Both vaccines produced mild side effects in some recipients, including pain at the injection site, fatigue, and muscle pain.

In evaluating the safety of Pfizer’s vaccine, the FDA identified one case of Guillain-Barré syndrome, a rare neurological disorder, and one case of Miller Fisher syndrome, a rare Guillain-Barré-related nerve disease.

The FDA also identified a case of Guillain-Barré that was potentially related to the GSK vaccine, as well as higher incidences of atrial fibrillation (irregular heart rhythm) among vaccine recipients relative to the trial control group.

Some members of the CDC advisory committee stressed the lack of data Wednesday on how well immunosuppressed people, those with underlying health conditions, and people older than 75 would tolerate the vaccines and pointed to limited evidence on whether second doses would increase the protection.

Members also raised concerns about the price. GSK said a single dose would cost between $200 and $295, and Pfizer estimated that a single dose would cost between $180 and $270. (However, those prices do not reflect what insured patients would pay.)

In addition to older adults, RSV can pose a major health threat to babies. But two tools to protect babies from the virus could also be available before the fall.

An independent FDA advisory committee voted last month to recommend Pfizer’s maternal RSV vaccine, which is given to pregnant mothers to protect their babies from RSV. The vaccine has the same formulation as the Pfizer shot for older adults.

This month’s FDA advisory panel also recommended an injectable drug that can protect babies up to 2 years of age from RSV. Pharmaceutical giant AstraZeneca developed the monoclonal antibody drug, called nirsevimab, in partnership with Sanofi. It is given as a single shot and works similar to a vaccine.

By Mitchell G. Patton

You May Also Like